Health & Medicine

STAT+: Pharmalittle: We're reading about TrumpRx shortcomings, Lilly targeting employers, and more

Ali NematiMar 531 sec read19 views

President Trump's drug discount platform, TrumpRx, has fallen short of expectations a month after launch, with limited availability and usage data, contrasting sharply with its promised impact on reducing medication costs. The FDA’s top drug regulator is pushing to add new warnings about pregnancy risks to antidepressants, reflecting ongoing debates over drug safety and labeling. For content creators, these developments highlight the importance of critically evaluating health policy claims and staying informed about regulatory changes affecting pharmaceuticals.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

STAT+: Pharmalittle: We're reading about Trump and drug prices, biotechs pushing back, and more

Trump is receiving more credit than Biden for efforts to lower drug prices in the U.S., according to a KFF poll, despite both administrations prioritizing this issue; biotech companies are openly opposing Trump's plan to cap drug prices, arguing it c...

Ali Nemati

Health & Medicine1 day ago23 sec read

STAT+: Is Aldeyra Therapeutics waving red flags with consequences?

Aldeyra Therapeutics has raised concerns about short sellers ahead of an FDA approval decision, signaling potential risks for investors; this highlights the scrutiny biotech companies face from market skeptics as they await critical regulatory milest...

Ali Nemati

Health & Medicine1 day ago25 sec read

Republicans Fret Over RFK Jr.'s Anti-Vaccine Policies While MAHA Moms Stew

Health and Human Services Secretary Robert F. Kennedy Jr. faces pressure to moderate his controversial vaccine policies as midterm elections approach, while maintaining support from his MAHA coalition focused on food safety and reducing chemical use ...

Ali Nemati

Health & Medicine1 day ago28 sec read

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them?

The FDA is targeting telehealth companies for misleading marketing of compounded GLP-1 weight loss drugs, warning them against implying FDA approval. The crackdown also implicates affiliated medical groups that prescribe these unapproved medications,...

Ali Nemati

Health & Medicine1 day ago20 sec read

Opinion: STAT+: It's the 50th anniversary of the U.S. biotech industry. What will the next 50 years look like?

The U.S. biotech industry celebrates its 50th anniversary since Genentech's founding in 1976, marking significant advancements in health and job creation; as content creators focus on this milestone, they should highlight the potential for future inn...

Ali Nemati

STAT+: Pharmalittle: We're reading about TrumpRx shortcomings, Lilly targeting employers, and more

Related Articles

STAT+: Pharmalittle: We're reading about Trump and drug prices, biotechs pushing back, and more

STAT+: Is Aldeyra Therapeutics waving red flags with consequences?

Republicans Fret Over RFK Jr.'s Anti-Vaccine Policies While MAHA Moms Stew

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them?

Opinion: STAT+: It's the 50th anniversary of the U.S. biotech industry. What will the next 50 years look like?